Avid Bioservices, Inc.

Equities

CDMO

US05368M1062

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-07-05 pm EDT 5-day change 1st Jan Change
7.42 USD -3.64% Intraday chart for Avid Bioservices, Inc. +3.92% +14.15%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Avid Bioservices Fiscal Q4 Loss Widens, Revenue Increases; Fiscal 2025 Revenue Outlook Set MT
Transcript : Avid Bioservices, Inc., Q4 2024 Earnings Call, Jul 02, 2024
Avid Bioservices, Inc. Reports Earnings Results for the Full Year Ended April 30, 2024 CI
Avid Bioservices Provides Earnings Guidance for Fiscal Year 2025 CI
Avid Bioservices, Inc.(NasdaqCM:CDMO) added to Russell Small Cap Comp Value Index CI
Avid Bioservices, Inc.(NasdaqCM:CDMO) added to Russell 2500 Value Index CI
Avid Bioservices, Inc.(NasdaqCM:CDMO) added to Russell 3000 Value Index CI
Avid Bioservices, Inc.(NasdaqCM:CDMO) added to Russell 2000 Value Index CI
Avid Bioservices, Inc.(NasdaqCM:CDMO) added to Russell Microcap Value Index CI
Avid Bioservices, Inc.(NasdaqCM:CDMO) added to Russell 3000E Value Index CI
RBC Lifts Price Target on Avid Bioservices to $8 From $7, Keeps Outperform Rating MT
Transcript : Avid Bioservices, Inc., Q3 2024 Earnings Call, Apr 29, 2024
Avid Bioservices, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024 CI
North American Morning Briefing : Stock Futures -2- DJ
North American Morning Briefing : Investors on Edge as High-Stakes Jobs Report Awaited DJ
North American Morning Briefing : Stocks Struggle After New Records DJ
Avid Bioservices Receives Nasdaq Noncompliance Notice MT
North American Morning Briefing : Inflation Worries Continue to Weigh on Mood DJ
Stephens Adjusts Price Target on Avid Bioservices to $12 From $15, Maintains Overweight Rating MT
Avid Bioservices Prices $160 Million Convertible Notes Offering; Shares Slump MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Buoyed by Powell's Comments MT
Top Premarket Decliners MT
Avid Bioservices Shares Slide After Pricing Private Placement of Convertible Notes DJ
Avid Bioservices Prices $160 Million Convertible Notes Offering MT
Avid Bioservices Preliminary Fiscal Q3 Revenue Falls 11%; $160 Million Private Placement of Notes Set; Shares Slump MT
Chart Avid Bioservices, Inc.
More charts
Avid Bioservices, Inc. is a dedicated contract development and manufacturing organization (CDMO) focused on development and Current Good Manufacturing Practices (CGMP) manufacturing of biologics. The Company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. Its services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the Company provides a variety of process development activities, including cell line development, upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of its services ranges from standalone process development projects to full development and manufacturing programs through commercialization. Commercial biologics produced by it are distributed to over 90 countries.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
7.42 USD
Average target price
12.5 USD
Spread / Average Target
+68.46%
Consensus
  1. Stock Market
  2. Equities
  3. CDMO Stock
  4. News Avid Bioservices, Inc.
  5. Avid Bioservices Prices $160 Million Convertible Notes Offering; Shares Slump